Ovid Therapeutics (OVID)

• Market cap: $20.5M
• 1 day: 6.53%
• 5 days: 3.44%
• 1 month: -38.08%
• 3 months: -61.00%
• 6 months: -75.33%
• Year to date: -69.87%
• 1 year: -90.72%
• 5 years: -91.51%
• 10 years: -97.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Employees: 23

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

9% more funds holding

Funds holding: 75 [Q3] → 82 (+7) [Q4]

1.71% more ownership

Funds ownership: 65.28% [Q3] → 66.99% (+1.71%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

19% less capital invested

Capital invested by funds: $54.7M [Q3] → $44.4M (-$10.3M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 940% upside
• Avg. target: $3.67 1,171% upside
• High target: $4 1,286% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

BTIG Thomas Shrader 11% 1-year accuracy 1 / 9 met price target	1,286% upside $4	Buy Maintained	24 Mar 2025
Wedbush Laura Chico 9% 1-year accuracy 4 / 46 met price target	940% upside $3	Outperform Maintained	12 Mar 2025
Oppenheimer Francois Brisebois 17% 1-year accuracy 5 / 30 met price target	1,286% upside $4	Outperform Upgraded	29 Jan 2025